BridgeBio Pharma, Inc.
BBP-418
limb-girdle muscular dystrophy type 2I/R9
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“FORTIFY, the Phase 3 clinical trial of BBP-418, successfully met all pre-specified primary and secondary endpoints of its 12-month interim analysis.”